PittockSJMcClellandRLMayrWT, et al. Clinical implications of benign multiple sclerosis: A 20-year population-based follow-up study. Ann Neurol2004; 56(2): 303–306.
2.
RoxburghRHSRSeamanSRMastermanT, et al. Multiple sclerosis severity score: Using disability and disease duration to rate disease severity. Neurology2005; 64: 1144–1151.
3.
WeinshenkerBGBassBRiceGP, et al. The natural history of multiple sclerosis: A geographically based study. I. Clinical course and disability. Brain1989; 112(Pt1): 133–146.
4.
ZivadinovRCookfairDLKruppL, et al. Factors associated with benign multiple sclerosis in the New York State MS consortium (NYSMSC). BMC Neurol2016; 16: 102.
5.
SchaeferLMPoettgenJFischerA, et al. Impairment and restrictions in possibly benign multiple sclerosis. Brain Behav2019; 9(4): e01259.
6.
CifelliAArridgeMJezzardP, et al. Thalamic neurodegeneration in multiple sclerosis. Ann Neurol2002; 52: 650–653.
7.
FisnikuLKChardDTJacksonJS, et al. Gray matter atrophy is related to long-term disability in multiple sclerosis. Ann Neurol2008; 64(3): 247–254.
8.
BenedettiBRovarisMRoccaMA, et al. In-vivo evidence for stable neuroaxonal damage in the brain of patients with benign multiple sclerosis. Mult Scler2009; 15(7): 789–794.
9.
CalabreseMFilippiMRovarisM, et al. Evidence for relative cortical sparing in benign multiple sclerosis: A longitudinal magnetic resonance imaging study. Mult Scler J2009; 15: 36–41.
10.
De StefanoNBattagliniMStromilloML, et al. Brain damage as detected by magnetization transfer imaging is less pronounced in benign than in early relapsing multiple sclerosis. Brain2006; 129(Pt8): 2008–2016.
